6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury

C. Delehouzé 1 S. Leverrier-Penna 2 F. Le Cann 2 A. Comte 3 M. Jacquard-Fevai 4, 5 O. Delalande 6 N. Desban 1 B. Baratte 1 I. Gallais 2 F. Faurez 2 M. C. Bonnet 2 M. Hauteville 7 P. G. Goekjian 3 R. Thuillier 8, 9, 5 F. Favreau 9, 5 P. Vandenabeele 10 T. Hauet 9, 11 Marie-Thérèse Dimanche-Boitrel 2 S. Bach 1 & Bach
3 CO2GLYCO - Chimie Organique 2-Glycochimie
ICBMS - Institut de Chimie et Biochimie Moléculaires et Supramoléculaires
11 FHU SUPORT - Fédération Hospitalo-universitaire SUrvival oPtimization in ORgan Transplantation
CHU Poitiers - Centre hospitalier universitaire de Poitiers , CHU Tours, RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques, CHU Limoges, IPPRITT - Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation, IRTOMIT - Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques, Cellules Dendritiques, Immunomodulation et Greffes
Abstract : Necroptosis is a programmed cell death pathway that has been shown to be of central pathophysiological relevance in multiple disorders (hepatitis, brain and cardiac ischemia, pancreatitis, viral infection and inflammatory diseases). Necroptosis is driven by two serine threonine kinases, RIPK1 (Receptor Interacting Protein Kinase 1) and RIPK3, and a pseudo-kinase MLKL (Mixed Lineage Kinase domain-Like) associated in a multi-protein complex called necrosome. In order to find new inhibitors for use in human therapy, a chemical library containing highly diverse chemical structures was screened using a cell-based assay. The compound 6E11, a natural product derivative, was characterized as a positive hit. Interestingly, this flavanone compound: inhibits necroptosis induced by death receptors ligands TNF-α (Tumor Necrosis Factor) or TRAIL (TNF-Related Apoptosis-Inducing Ligand); is an extremely selective inhibitor, among kinases, of human RIPK1 enzymatic activity with a nM Kd; has a non-ATP competitive mode of action and a novel putative binding site; is weakly cytotoxic towards human primary blood leukocytes or retinal pigment epithelial cells at effective concentrations; protects human aortic endothelial cells (HAEC) from cold hypoxia/reoxygenation injury more effectively than necrostatin-1 (Nec-1) and Nec-1s. Altogether, these data demonstrate that 6E11 is a novel potent small molecular inhibitor of RIPK1-driven necroptosis.
Keywords : Necroptosis
Type de document :
Article dans une revue
Scientific Reports, Nature Publishing Group, 2017, 7 (1), pp.12931. 〈10.1038/s41598-017-12788-4〉
Liste complète des métadonnées

Littérature citée [24 références]  Voir  Masquer  Télécharger

Contributeur : Xavier Chard-Hutchinson <>
Soumis le : vendredi 27 octobre 2017 - 14:28:06
Dernière modification le : jeudi 6 décembre 2018 - 01:30:02


Fichiers éditeurs autorisés sur une archive ouverte



C. Delehouzé, S. Leverrier-Penna, F. Le Cann, A. Comte, M. Jacquard-Fevai, et al.. 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury. Scientific Reports, Nature Publishing Group, 2017, 7 (1), pp.12931. 〈10.1038/s41598-017-12788-4〉. 〈hal-01616456〉



Consultations de la notice


Téléchargements de fichiers